1. Cancer Biology
Download icon

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

  1. Teresa Fan  Is a corresponding author
  2. Richard M Higashi
  3. Huan Song
  4. Saeed Daneshmandi
  5. Angela L Mahan
  6. Matthew S Purdom
  7. Therese J Bocklage
  8. Thomas A Pittman
  9. Daheng He
  10. Chi Wang
  11. Andrew N Lane  Is a corresponding author
  1. University of Kentucky, United States
  2. Baptist Health, United States
Research Article
  • Cited 0
  • Views 363
  • Annotations
Cite this article as: eLife 2021;10:e69578 doi: 10.7554/eLife.69578

Abstract

Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development. A better understanding of the drug's action is needed to improve patient outcomes. Functional heterogeneity of the tumor microenvironment (TME) is crucial to modulating drug resistance; understanding of individual patients' TME that impacts drug response is hampered by lack of appropriate models. Lung organotypic tissue slice cultures (OTC) with patients' native TME procured from primary and brain-metastasized (BM) non-small cell lung cancer (NSCLC) patients were treated with Pembrolizumab and/or beta-glucan (WGP, an innate immune activator). Metabolic tracing with 13C6-Glc/13C5,15N2-Gln, multiplex immunofluorescence (mIF), and digital spatial profiling (DSP) were employed to interrogate metabolic and functional responses to Pembrolizumab and/or WGP. Primary and BM PD-1+ lung cancer OTC responded to Pembrolizumab and Pembrolizumab + WGP treatments, respectively. Pembrolizumab activated innate immune metabolism and functions in primary OTC, which were accompanied by tissue damage. DSP analysis indicated an overall decrease in immunosuppressive macrophages and T cells but revealed microheterogeneity in immune responses and tissue damage. Two TMEs with altered cancer cell properties showed resistance. Pembrolizumab or WGP alone had negligible effects on BM-lung cancer OTC but Pembrolizumab + WGP blocked central metabolism with increased pro-inflammatory effector release and tissue damage. In depth metabolic analysis and multiplex TME imaging of lung cancer OTC demonstrated overall innate immune activation by Pembrolizumab but heterogeneous responses in the native TME of a patient with primary NSCLC. Metabolic and functional analysis also revealed synergistic action of Pembrolizumab and WGP in OTC of metastatic NSCLC.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Excel spreadsheets of data used for tables and figures will be deposited at Dryad.

The following data sets were generated

Article and author information

Author details

  1. Teresa Fan

    University of Kentucky, LEXINGTON, United States
    For correspondence
    teresa.fan@uky.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7292-8938
  2. Richard M Higashi

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Huan Song

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Saeed Daneshmandi

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Angela L Mahan

    Baptist Health, Louisville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Matthew S Purdom

    Deptartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Therese J Bocklage

    Deptartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas A Pittman

    Department of Neurosurgery, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Daheng He

    Deptartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Chi Wang

    Deptartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Andrew N Lane

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    For correspondence
    andrew.lane@uky.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Surgical patients were consented for freshly resected tissue specimens under the approved IRB protocol (14-0288-F6A; 13-LUN-94-MCC) of the University of Kentucky (UKy).

Reviewing Editor

  1. Fabio Malavasi, University of Torino Medical School, Italy

Publication history

  1. Received: April 20, 2021
  2. Accepted: July 26, 2021
  3. Accepted Manuscript published: August 18, 2021 (version 1)
  4. Accepted Manuscript updated: August 20, 2021 (version 2)
  5. Accepted Manuscript updated: August 31, 2021 (version 3)

Copyright

© 2021, Fan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 363
    Page views
  • 69
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Medicine
    Maria Ochoa de Olza
    Insight

    Organ-on-chip approaches could help researchers to better predict the toxicity of cancer immunotherapy drugs.

    1. Cancer Biology
    2. Cell Biology
    Brian Spurlock et al.
    Short Report

    Gene knockout of the master regulator of mitochondrial fission, Drp1, prevents neoplastic transformation. Also, mitochondrial fission and its opposing process of mitochondrial fusion are emerging as crucial regulators of stemness. Intriguingly, stem/progenitor cells maintaining repressed mitochondrial fission are primed for self-renewal and proliferation. Using our newly derived carcinogen transformed human cell model we demonstrate that fine-tuned Drp1 repression primes a slow cycling 'stem/progenitor-like state', which is characterized by small networks of fused mitochondria and a gene-expression profile with elevated functional stem/progenitor markers (Krt15, Sox2 etc) and their regulators (Cyclin E). Fine tuning Drp1 protein by reducing its activating phosphorylation sustains the neoplastic stem cell markers. Whereas, fine-tuned reduction of Drp1 protein maintains the characteristic mitochondrial shape and gene-expression of the primed 'stem/progenitor-like state' to accelerate neoplastic transformation, and more complete reduction of Drp1 protein prevents it. Therefore, our data highlights a 'goldilocks'; level of Drp1 repression supporting stem/progenitor state dependent neoplastic transformation.